Evidence-focused medical education. CJC-1295 and ipamorelin are peptides promoted by some wellness sources as growth-hormone secretagogues. Neither should be presented as an FDA-approved weight-loss, anti-aging or body-composition treatment. Our approach begins with the patient’s diagnosis, goals and objective medical evaluation rather than assuming a peptide is appropriate.
CJC-1295 is a growth-hormone-releasing hormone analog studied for its effects on growth hormone and IGF-1 signaling. Ipamorelin is a growth-hormone secretagogue that acts through the ghrelin receptor. They are sometimes marketed together, but marketing claims about synergy, fat loss, muscle gain, sleep, recovery or anti-aging should not be confused with established clinical outcomes.
FDA has identified CJC-1295 and ipamorelin acetate among bulk substances that may present significant safety risks in compounding. FDA notes limited clinical data for CJC-1295 and has identified serious adverse events including increased heart rate and systemic vasodilatory reaction. For ipamorelin, FDA describes immunogenicity and characterization concerns and states that safety information is insufficient for certain injectable routes. Read the FDA safety-risk information.
Symptoms commonly attributed online to “low growth hormone”—such as fatigue, poor recovery, changes in body composition or reduced exercise performance—are nonspecific. Depending on the clinical picture, evaluation may include metabolic, thyroid, nutritional, hormonal or other testing. The purpose is to identify treatable causes rather than prescribe based on symptoms alone.
Learn more from our Peptide Therapy Los Angeles hub, Peptides & Metabolic Health, Nutrition & Body Composition, and Medical Weight Loss.
No. They are not FDA-approved weight-loss treatments.
No. Changes in a hormone biomarker do not establish meaningful anti-aging benefit, and anti-aging claims require much stronger clinical evidence.
No. FDA does not approve compounded drugs or review them before marketing for safety, effectiveness or quality in the same way it reviews approved drug products.
The answer depends on the goal. Weight management, true endocrine disorders, sleep problems, nutritional deficiencies and body-composition concerns each have different evidence-based evaluation and treatment pathways.
